Iverscab 12mg Dispersible Tablet contains Ivermectin 12mg, an antiparasitic agent effective against a variety of parasitic infections. Ivermectin acts by binding selectively to glutamate-gated chloride ion channels in the nerve and muscle cells of invertebrates, leading to increased permeability to chloride ions, hyperpolarization, paralysis, and death of the parasite. This formulation is designed as a dispersible tablet, allowing for ease of administration, particularly in patients with difficulty swallowing conventional tablets. Iverscab is indicated for the treatment of onchocerciasis (river blindness), strongyloidiasis, and other parasitic infestations caused by susceptible nematodes. The dispersible nature of the tablet facilitates rapid dissolution in water, ensuring prompt absorption and onset of action. Dosage should be individualized based on the patient’s weight and the specific parasitic infection being treated, with careful adherence to prescribed regimens to avoid resistance development. Common adverse effects may include mild gastrointestinal disturbances, dizziness, and transient pruritus. Iverscab should be used with caution in patients with impaired liver function or those concurrently receiving other neurotoxic drugs. It is contraindicated in patients with known hypersensitivity to Ivermectin or any excipients. Consultation with a healthcare professional is essential before initiating therapy to ensure appropriate use and monitoring.